Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
3,669 results
  • Cardioembolic stroke in a young male with cor triatriatum sinister: a case report. [Case Reports]
    Eur Heart J Case Rep. 2020 Jun; 4(3):1-6.Amara RS, Lalla R, … Hong SN
  • Cor triatriatum sinister (CTS) is a rare congenital cardiac anomaly defined by a fibromuscular membrane which bisects the left atrium. Cor triatriatum sinister has been associated with cardioembolic stroke through mechanisms including stagnation of blood flow within the left atrium, an association with atrial fibrillation (AF), and/or an accompanying atrial septal defect (ASD) or patent foramen o…
  • Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry. [Journal Article]
    TH Open. 2020 Apr; 4(2):e127-e137.Ferrandis R, Llau JV, … RA-ACOD investigators
  • Introduction  There is scarce real-world experience regarding direct oral anticoagulants (DOACs) perioperative management. No study before has linked bridging therapy or DOAC-free time (pre-plus postoperative time without DOAC) with outcome. The aim of this study was to investigate real-world management and outcomes. Methods  RA-ACOD is a prospective, observational, multicenter registry of adult …
  • Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. [Journal Article]
    TH Open. 2020 Apr; 4(2):e119-e126.Hendriks SV, Klok FA, … Huisman MV
  • Introduction  Phase 3 trials have shown comparable efficacy of direct oral anticoagulants (DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE), with less major bleeding events in patients randomized to DOAC treatment. With DOACs being increasingly used in clinical practice, evaluation of the DOACs in daily practice-based conditions is needed to confirm their safet…
  • Oral Anticoagulants - Utilisation and Expenditure under the Community Drugs Schemes. [Journal Article]
    Ir Med J. 2020 May 07; 113(5):71.Smith A, Barry M
  • Aims This study determined the impact of the direct oral anticoagulants (DOACs) on the utilisation and expenditure on oral anticoagulants (OACs) in the Irish Community healthcare setting. We also investigated aspects of DOAC prescribing. Methods Using anonymised prescription data from the HSE pharmacy claims database we investigated anticoagulant prescribing over the study period (1/1/2014 - 31/1…
  • Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. [Journal Article]
    ESC Heart Fail. 2020 Jun 25 [Online ahead of print]Iqbal H, Straw S, … Witte KK
  • CONCLUSIONS: Our data suggest that DOACs are likely to be at least as effective and safe as VKA for stroke prevention in patients with LV thrombus and, despite their lack of a licence for this indication, are therefore likely to represent a reasonable and more convenient option for this setting. The optimal timing and type of anticoagulation for LV thrombus, as well as the role of screening for high-risk patients, should be tested in prospective, randomized trials.
  • A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding. [Journal Article]
    Rev Recent Clin Trials. 2020 Jun 24 [Online ahead of print]Ojetti V, Saviano A, … Franceschi F
  • CONCLUSIONS: Although these agents have been marketed for five years (idarucizumab) and two years (andexanet alfa) respectively, and despite guidelines considering antidotes as first-line agents in treating life-threatening hemorrhage when available, these antidotes seem to gain access very slowly in the clinical practice. Cost, logistical aspects and need for plasma level determination of DOAC for an accurate therapeutic use probably have an impact on this phenomenon.. An expert multidisciplinary bleeding team should be established so as to implement international guidelines based on local resources and organization.
  • Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant. [Journal Article]
    Curr Med Res Opin. 2020 Jun 23 [Online ahead of print]Mitrovic D, Folkeringa R, … van Roon E
  • Aims: We sought to investigate the magnitude of minor bleeding and identify risk factors for minor bleeds during non-vitamin K antagonist oral anticoagulant (NOAC) therapy.Methods: This was an observational cohort study of patients with atrial fibrillation (AF) referred to a regional NOAC outpatient clinic between February 2013 and October 2017. The study population consisted of 875 consecutive…
  • Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system. [Journal Article]
    Res Pract Thromb Haemost. 2020 May; 4(4):619-627.Pfrepper C, Metze M, … Petros S
  • CONCLUSIONS: TG parameters measured with ST Genesia correlate with the drug levels of anti-Xa DOACs. Peak thrombin and velocity index are of special interest for the determination of residual anticoagulant effect at low drug levels. For dabigatran-treated patients, only lag time shows a correlation with the dabigatran plasma levels.
  • Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants. [Journal Article]
    Res Pract Thromb Haemost. 2020 May; 4(4):610-618.Metze M, Pfrepper C, … Petros S
  • CONCLUSIONS: Thrombin generation remains reduced 12 hours after DOAC intake. While thrombin peak is particularly modified by factor Xa inhibitors, all DOACs prolong the lag time and time to thrombin peak. In the setting of bleeding or urgent surgery, the automated thrombin generation assay may assist in decision making and antidote administration.
  • Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. [Review]
    Res Pract Thromb Haemost. 2020 May; 4(4):532-549.Bauersachs R, Khorana AA, … Soff G
  • Cancer-associated venous thromboembolism (VTE) is a frequent, potentially life-threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer-associated thrombosis (CAT); factor Xa-inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of …
  • Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. [Journal Article]
    Stroke. 2020 Jun 16 [Online ahead of print]Van Ganse E, Danchin N, … Steg PG
  • CONCLUSIONS: Apixaban was associated with superior safety, effectiveness, and lower mortality than VKAs; with superior safety than rivaroxaban and similar safety to dabigatran; and with similar effectiveness when compared with rivaroxaban or dabigatran. These observational data suggest potentially important differences in outcomes between direct oral anticoagulants, which should be explored in randomized trials.
  • What gastroenterologists should know about direct oral anticoagulants. [Review]
    Dig Liver Dis. 2020 Jun 09 [Online ahead of print]Radaelli F, Fuccio L, … Dentali F
  • Direct oral anticoagulants are being increasingly used in patients with non-valvular atrial fibrillation and venous thromboembolism, due to their improved efficacy/ safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with vitamin K antagonists. Gastrointestinal bleeding remains a serious complication, whos…
  • Prophylaxis of venous thromboembolism disease in patients with cancer. [Review]
    Rev Clin Esp. 2020 Jun 09 [Online ahead of print]Portillo Sánchez J
  • Thrombotic risk should always be assessed in the various clinical scenarios of patients with cancer. Thromboprophylaxis with low-molecular-weight heparin is recommended above other anticoagulants for most patients with cancer who are hospitalised. However, the safety of primary thromboprophylaxis in this context is unknown; however, thromboprophylaxis can be completed with mechanical methods. Thr…
New Search Next